Cancer Genetics to Aid Lantern Pharma in Biomarker, Dx Development

Jan 17, 2017

|

NEW YORK (GenomeWeb) – Cancer Genetics said today that it has signed a collaboration agreement to aid precision therapeutics firm Lantern Pharma in biomarker discovery, clinical trials, and genomics projects for its lead drug candidates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Prize for Five

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Sure, Blame the Test

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

This Week in Genome Research

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Low Down Syndrome Rates in Iceland

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.

Featured White Papers

BioNano Genomics’ Next-Generation Mapping Identifies Large Structural Variants in Cancer and Genetic Disorders

Albumin & IgG Removal Reference Applications

Compatibility of POLYVIEW IHC Detection Reagents and HIGHDEF IHC Chromogens with Automated IHC Slide Stainers

Sep

20

Featured Webinar

Latest Advances in Tumor Genomic Profiling for Challenging Samples

This webinar will discuss how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.

Sep

21

Featured Webinar

Processing Challenging Tumor Samples via Automated Tissue Dissection and Extraction-Free Library Prep

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep

27

Featured Webinar

Large-scale, Prospective Tumor and Normal Sequence to Accelerate Biomarker Discovery and Guide Clinical Care

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Main menu